AAPG News & Events

Ascentage Pharma announced that its novel next-generation BTK-targeted protein degrader, APG-3288, has received the IND clearance from the U.S. Food and Drug Administration and is poised to enter a clinical study in patients with relapsed/refractory B-cell malignancies. This clearance officially opens the chapter on Ascentage Pharma's clinical development in the field of targeted degradation and marks another major expansion to the company's global innovative pipeline, the company said. This is a global, multicenter, open-label Phase I study designed to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of APG-3288 in patients with relapsed/refractory hematologic malignancies.

Ascentage Pharma Group announced that it presented the latest results from a Phase Ib/II study of Lisaftoclax, a key investigational drug candidate in the Company's pipeline, in combination with azacitidine in patients with newly diagnosed or prior venetoclax-exposed myeloid malignancies in a poster presentation at the 67th American Society of Hematology, ASH, Annual Meeting, being held in Orlando, Florida. Data featured in the report further validated the therapeutic potential and favorable tolerability profile of Lisaftoclax in myeloid malignancies, including treatment responses from venetoclax-resistant patients. These results underscore Lisaftoclax's distinct clinical value that is differentiated from other drugs in the same class.